ライフサイエンスコーパス: patients in

1 rgery that were rated as inappropriate decreased from 2,956 patients in 2010 to 911 patients in 2014, a reduction of 69%.

2 inappropriate decreased from 2,956 patients in 2010 to 911 patients in 2014, a reduction of 69%.

3 , in HIV disease progression by analyzing a large number of patients in 3 cohorts with different HIV disease progression

4 e a framework for future tailoring, triage, and therapy for patients in a more personalized and precise manner.

5 Results Only two of the 35 patients in ACOSOG Z1031B who were switched to neoadjuvant ch

6 ally bootstrap validated, and externally validated in 1,547 patients in another study.

7 Patients in both cohorts were adults (>/=18 years in England,

8 ohort (representative of Italian hepatitis C virus-infected patients in care).

9 old was younger for Chinese patients than that reported for patients in developed countries.

10 Bidirectional block was achieved in 56 of 57 patients in group A (98.2%) and 50 of 57 patients in group B

11 hieved in 56 of 57 patients in group A (98.2%) and 50 of 57 patients in group B (87.7%; P=0.06).

12 has been challenging to use genetic profiles of individual patients in identifying the most appropriate anti-cancer drug

13 There is a major unmet need to identify high-risk patients in myocarditis.

14 Ticagrelor appears to provide higher value for patients in several recognized high-risk subgroups.

15 Also, 39% of patients in the 170-mug group became nonreactive to CPT vs 18

16 erosclerotic stenosis interaction in a subgroup analysis of patients in the Acute Stroke or Transient Ischaemic Attack Tr

17 Of 127 patients in the AIM Dysplasia trial, 119 received RFA and met

18 red in 22% of patients in the control group and none of the patients in the alcohol-free group.

19 Both models remained effective after inclusion of older patients in the analysis.

20 Patients in the BL group had a mean increase in quality of li

21 rse events of grade 3 or higher were reported in 87% of the patients in the blinatumomab group and in 92% of the patients

22 of the patients in the blinatumomab group and in 92% of the patients in the chemotherapy group.

23 Minor adverse events occurred in 22% of patients in the control group and none of the patients in the

24 Of 4584 patients in the database, 2697 were included in our analysis

25 Among 638 patients in the derivation cohort, 121 (18.9%) had CED.

26 Nonsentinel-node metastases, identified in 11.5% of the patients in the dissection group, were a strong, independent

27 of DM and the glycosylated hemoglobin (HbA1c) levels of the patients in the DM group were recorded.

28 to be associated with a 38% excess fracture risk among T2DM patients in the early stages of the disease.

29 any grade) prompted treatment discontinuation in four (11%) patients in the every-12-weeks cohort and five (13%) patients

30 (11%) patients in the every-12-weeks cohort and five (13%) patients in the every-6-weeks cohort.

31 100 (40%) of 249 patients in the full analysis set achieved a response, with 1

32 odies was similar in the treatment groups (five [2%] of 268 patients in the GP2013-CVP; three [1%] in the R-CVP group).

33 Among patients in the ICU requiring intubation, video laryngoscopy

34 Among the patients in the imatinib group, the estimated overall surviva

35 icant difference observed between wildtype and heterozygous patients in the majority of the outcomes studied.

36 Serious adverse events were experienced by 35 (18%) patients in the olaparib group and eight (8%) patients in the

37 of grade 3 or worse severity were anaemia (38 [19%] of 195 patients in the olaparib group vs two [2%] of 99 patients in

38 disease (n=2 in the PENFS group; n=1 in the sham group), 57 patients in the PENFS group and 47 patients in the sham group

39 he patients in the tranexamic acid group and in 2.8% of the patients in the placebo group (P=0.001), and seizures occurre

40 9%] of 195 patients in the olaparib group vs two [2%] of 99 patients in the placebo group), fatigue or asthenia (eight [4

41 d by 35 (18%) patients in the olaparib group and eight (8%) patients in the placebo group.

42 3 (62%) of 102 patients underwent PCS versus 93 (94%) of 99 patients in the primary surgery group.

43 Definite or probable device thrombosis occurred in 31 patients in the scaffold group as compared with 8 patients in

44 1 in the sham group), 57 patients in the PENFS group and 47 patients in the sham group were included in the primary analy

45 red in 31 patients in the scaffold group as compared with 8 patients in the stent group (2-year cumulative event rates, 3

46 ac tamponade leading to reoperation occurred in 1.4% of the patients in the tranexamic acid group and in 2.8% of the pati

47 in whole blood samples from 150 participants, representing patients in the upper and lower quartile of BP response to TD

48 In the randomly assigned patients, 21 patients in the VRd group and 31 in the Rd group were deemed

49 The rate of depression among the patients in this study was comparable to those reported in pr

50 We then retrospectively compared the patients in this study with all other concurrent patients at

51 We pooled patients in whom (non-V600) BRAF mutations were identified fr